Context Therapeutics Inc.
General ticker "CNTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $143.7M (TTM average)
Context Therapeutics Inc. follows the US Stock Market performance with the rate: 10.4%.
Estimated limits based on current volatility of 5.9%: low 0.57$, high 0.64$
Factors to consider:
- Total employees count: 5 (-44.4%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Manufacturing risks, Key person loss
- Current price 26.3% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.81$, 2.04$]
- 2026-12-31 to 2027-12-31 estimated range: [0.83$, 2.03$]
Financial Metrics affecting the CNTX estimates:
- Positive: with PPE of -3.2 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -4.39 < Investing cash flow per share per price, % of -1.76
- Positive: Shareholder equity ratio, % of 88.29 > 64.23
Short-term CNTX quotes
Long-term CNTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $25.07MM | $29.92MM | $39.70MM |
| Operating Income | $-25.07MM | $-29.92MM | $-39.70MM |
| Non-Operating Income | $1.11MM | $3.20MM | $3.58MM |
| R&D Expense | $17.78MM | $22.70MM | $31.86MM |
| Income(Loss) | $-23.96MM | $-26.72MM | $-36.12MM |
| Net Income(Loss)* | $-23.96MM | $-26.73MM | $-36.12MM |
| Stockholders Equity | $11.87MM | $95.27MM | $60.47MM |
| Assets | $16.06MM | $98.13MM | $68.49MM |
| Operating Cash Flow | $-21.05MM | $-14.56MM | $-26.39MM |
| Capital expenditure | $0.00MM | $14.76MM | $0.03MM |
| Investing Cash Flow | $0.00MM | $-14.76MM | $-2.03MM |
| Financing Cash Flow | $0.00MM | $109.29MM | $-0.02MM |
| Earnings Per Share** | $-1.50 | $-0.46 | $-0.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.